284462-44-8

Basic information

• Product Name: 2-Pyridinecarboxamide, 4-(4-amino-3-chlorophenoxy)-N-methyl-
• CAS NO: 284462-44-8
• Molecular Formula: C13H12ClN3O2
• Molecular Weight: 277.71
• Mol File: 284462-44-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-Pyridinecarboxamide, 4-(4-amino-3-chlorophenoxy)-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxamide, 4-(4-amino-3-chlorophenoxy)-N-methyl-(284462-44-8)
• EPA Substance Registry System: 2-Pyridinecarboxamide, 4-(4-amino-3-chlorophenoxy)-N-methyl-(284462-44-8)

Safety Data

• Hazardous Substances Data: 284462-44-8(Hazardous Substances Data)

Upstream product

• 17609-80-2 4-amino-3-chlorophenol 
• 7440-44-0 pyrographite 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 41513-02-4 4-bromo-3-(trifluoromethyl)phenyl isocyanate 
• 284462-45-9 4-chloro-2-methoxy-5-(trifluoromethyl)phenylaniline 
• 284462-99-3 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate 
• 284462-43-7 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl-(2,2,2-trifluoro)acetamide 

Downstream Products

• 284462-92-6 3-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-4-methylaniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-83-5 4-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-3-chloroaniline 

Relevant articles and documents

HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER

The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}-carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-carboxamide and alternatives forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and metabolites); pharmaceutical compositions which contain them and methods for treating cancer using them.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.